November 9–13, 2023, Anaheim, California, USA

American College Of Allergy, Asthma & Immunology

(ACAAI)

November 10–14, 2022, Louisville, KY

American College Of Allergy, Asthma & Immunology

(ACAAI)

American College Of Allergy, Asthma & Immunology

(ACAAI)

poster icon

Remibrutinib Provides Fast and Clinically Important Improvement of Chronic Spontaneous Urticaria Disease Activity

J. Jacobs, M. Maurer, A.M. Giménez-Arnau, S. Savic, C-E. Ortmann, B. Suryawanshi, I. Nikolaev,
S. Haemmerle
poster icon

Remibrutinib Treatment Has No Impact on Blood Counts in Patients with Chronic Spontaneous Urticaria

J. Leflein, M. Hide, K. Lheritier, S. Haemmerle, M. Wells, M. Kuruvilla, A. Zharkov, A.M. Giménez-Arnau
poster icon

Remibrutinib Achieves Clinically Significant Response in Chronic Spontaneous Urticaria Patients Regardless of Prior Oral Treatments

L. Clore, M. Maurer, M. Wells, C-E. Ortmann, B. Suryawanshi, M. Kuruvilla, S. Haemmerle, A.M.Giménez-Arnau
poster icon

Analysis Of Safety Data Of Remibrutinib From Completed Phase 2 Studies In Inflammatory Immune-Mediated Diseases

S. Saini, M. Maurer, A.M. Giménez-Arnau, M. Hide, G. Sussman, S. Haemmerle, N. Barbier,
A. Zharkov
poster icon

Remibrutinib Treatment Improves Hive Severity in Patients With Chronic Spontaneous Urticaria: Phase 2b Study Results

K. Sitz, A.M. Giménez-Arnau, K. Hayama, V. Jain, K. Lheritier, P. Walsh, S. Haemmerle, M. Maurer
poster icon

Remibrutinib Did Not Impact on Total Serum Immunoglobulin Levels of Patients with Chronic Spontaneous Urticaria

W. Carr, A.M. Giménez-Arnau, K. Lheritier, S. Haemmerle, A. Zharkov, S. Dahale, K. Hayama
poster icon

Remibrutinib Showed Good Stability of Response in Patients With Chronic Spontaneous Urticaria: Phase 2b Study

J. Tillinghast, V. Jain, M. Maurer, A.M. Giménez-Arnau, A. Reich, C-E. Ortmann, P. Walsh,
S. Haemmerle
poster icon

Fast Symptom Improvement and Favorable Safety Profile With Remibrutinib in Chronic Spontaneous Urticaria: REMIX 1 and 2 Studies

S. Saini, A.M. Giménez-Arnau, M. Hide, M. Lebwohl, G. Sussman, A. Barron, S. Haemmerle, I. Hampele, K. Lheritier, E. Martzloff, A. Zharkov, M. Maurer
poster icon

Systemic Manifestations During Symptomatic Episodes In Chronic Spontaneous Urticaria: Results From The Urticaria Voices Study

J.A. Bernstein, T.A. Winders, T. Raftery, P. Saraswat, J. McCarthy, M. Kuruvilla, M-M. Balp, K Weller
poster icon

The Urticaria Voices Study: Antihistamine Treatment Patterns And Patient Reported Control In Chronic Spontaneous Urticaria

J.A. Bernstein, M-M. Balp, J. McCarthy, M. Kuruvilla, P. Saraswat, T. Raftery, T.A. Winders, K. Weller
poster icon

Remibrutinib treatment improves sleep and activity in chronic spontaneous urticaria patients: Phase 2b study results

L. Clore, V. Jain, A. Giménez-Arnau, K. Lheritier, P. Walsh, S. Haemmerle, M. Maurer
poster icon

Remibrutinib improves chronic spontaneous urticaria in patients irrespective of CU-Index: Results from Phase 2b study

W. Carr, K. Sitz, V. Jain, A. Giménez-Arnau, K. Lheritier, I. Nikolaev, S. Haemmerle, M. Maurer
poster icon

Remibrutinib improves chronic spontaneous urticaria in patients with low or high baseline IgE level

K. Hayama, A. Ramsey, M. Maurer, M. Hide, K. Lheritier, A. Zharkov, I. Nikolaev, S. Haemmerle
poster icon

Freedom from itch and hives in chronic spontaneous urticaria is associated with improved quality-of-life measures

J. A. Bernstein, A. Giménez-Arnau, M. Maurer, K. Sitz, G. Sussman, C-E. Ortmann, M-M. Balp, T. Severin

2021

poster icon

Complete response with ligelizumab in chronic spontaneous urticaria: A composite score of symptoms and quality-of-life

J. A. Bernstein, A. M. Giménez-Arnau, M. Hide, M. Maurer, K. Sitz, G. Sussman, P. Terradas-Montana, N. Barbier, T. Severin
poster icon

Ligelizumab achieves freedom from disease activity in chronic spontaneous urticaria regardless of previous H1-antihistamine dose

W. Soong, K. Sitz, J. A. Bernstein, M. Maurer, A. M. Giménez-Arnau, E. Hua, T. Severin

2020

poster icon

Complete control of urticaria symptoms with ligelizumab helps normalize quality of life

J. A. Bernstein, M. Maurer, A. Giménez-Arnau, W. Soong, M. Metz, N. Barbier, A. Barve, T. Severin, M-M. Balp, R. Janocha
poster icon

Sleep and quality of life improves with better control of urticaria symptoms: Ligelizumab phase-2b studies

R. Janocha, A. Giménez-Arnau, M. Maurer, J. A. Bernstein, N. Barbier, E. Hua, T. Severin, M-M. Balp
Thumb icon

Ligelizumab achieves fast control of symptoms in numerically more patients with chronic spontaneous urticaria versus omalizumab

T. Severin, W. Soong, M. Maurer, A. Giménez-Arnau, M. Hide, J. A. Bernstein, E. Hua, A. Barve, R. Janocha
Thumb icon

Efficacy of ligelizumab in patients with chronic spontaneous urticaria inadequately controlled with omalizumab

G. Sussman, K. Sitz, M. Metz, M. Hide, M. Maurer, B. Barbier, E. Hua, R. Janocha, T. Severin

2019

poster icon

Ligelizumab reduces rescue medication use in patients with chronic spontaneous urticaria: Phase 2b study results

K. Sitz, W. Soong, B. Lanier, K. Kobayashi, A. Barve, E. Hua, R. Janocha, T. Severin
Thumb icon

Ligelizumab achieves sustained control of angioedema in patients with chronic spontaneous urticaria

W. Soong, B. Lanier, K. Sitz, K. Kobayashi, A. Barve, E. Hua, R. Janocha, T. Severin
© Copyright 2024 Novartis Pharma AG